The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 7th 2024
Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.
26th Annual International Lung Cancer Congress®
July 24-26, 2025
Register Now!
San Diego Lung Symposia
September 7, 2024 - September 9, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Intensive Chemotherapy Boosts Prognosis in Older Teens With Acute Lymphoblastic Leukemia
New data demonstrate that older adolescents with acute lymphoblastic leukemia (ALL) can be cured using risk-adjusted intensive chemotherapy without prophylactic cranial irradiation or routine stem cell transplantation.
ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL
March 10th 2011Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia
ASH 2010: Ponatinib Inhibits Mutations That Block Treatment Paths for CML, ALL, and AML
March 10th 2011An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.
ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients
March 9th 2011Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.
ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma
March 9th 2011An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.
ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia
March 9th 2011Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.
ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients
March 9th 2011In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).